About Adimab
Adimab is a company based in Lebanon (United States) founded in 2007 by Errik Anderson.. Adimab has raised $35.39 million across 6 funding rounds from investors including Orbimed, Google Ventures and Borealis Ventures. The company has 121 employees as of December 31, 2021. Adimab offers products and services including Yeast-based Platform and T Cell Engager Platform. Adimab operates in a competitive market with competitors including Aphios, CDI Labs, OmniAb, QuaDRAD and AbCheck, among others.
- Headquarter Lebanon, United States
- Employees 121 as on 31 Dec, 2021
- Founders Errik Anderson
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adimab, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$35.39 M (USD)
in 6 rounds
-
Latest Funding Round
$14 M (USD), Series F
Apr 02, 2012
-
Investors
Orbimed
& 4 more
-
Employee Count
121
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adimab
Adimab offers a comprehensive portfolio of products and services, including Yeast-based Platform and T Cell Engager Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Generates human antibodies and multispecifics for therapeutics.
Develops multispecific leads for immune therapies.
Unlock access to complete
Unlock access to complete
Funding Insights of Adimab
Adimab has successfully raised a total of $35.39M across 6 strategic funding rounds. The most recent funding activity was a Series F round of $14 million completed in April 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series F — $14.0M
-
First Round
First Round
(20 Jul 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2012 | Amount | Series F - Adimab | Valuation |
investors |
|
| Nov, 2010 | Amount | Series E - Adimab | Valuation | Google Ventures , Borealis Ventures |
|
| Oct, 2009 | Amount | Series D - Adimab | Valuation | Google Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adimab
Adimab has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Google Ventures and Borealis Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in seed & series A startups
|
Founded Year | Domain | Location | |
|
US focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adimab
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adimab
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adimab Comparisons
Competitors of Adimab
Adimab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aphios, CDI Labs, OmniAb, QuaDRAD and AbCheck, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cancer and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Autoantibody detection and profiling products and services are provided.
|
|
| domain | founded_year | HQ Location |
Transgenic animal platforms are developed for human therapeutic antibody production.
|
|
| domain | founded_year | HQ Location |
Antibody drug discovery platform
|
|
| domain | founded_year | HQ Location |
Developer of human therapeutic antibodies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adimab
Frequently Asked Questions about Adimab
When was Adimab founded?
Adimab was founded in 2007.
Where is Adimab located?
Adimab is headquartered in Lebanon, United States.
Is Adimab a funded company?
Adimab is a funded company, having raised a total of $35.39M across 6 funding rounds to date. The company's 1st funding round was a Series D of $8.21M, raised on Jul 20, 2007.
How many employees does Adimab have?
As of Dec 31, 2021, the latest employee count at Adimab is 121.
What does Adimab do?
Adimab was founded in 2007 and is based in Lebanon, United States. Operations focus on the biotechnology sector, where an antibody discovery and optimization platform is utilized for autoimmune and infectious diseases. Diverse panels of therapeutically relevant antibodies are delivered and refined to satisfy criteria including affinity, epitope coverage, species cross-reactivity, and developability. The platform supports research and development needs in these therapeutic areas.
Who are the top competitors of Adimab?
What products or services does Adimab offer?
Adimab offers Yeast-based Platform and T Cell Engager Platform.
Who are Adimab's investors?
Adimab has 5 investors. Key investors include Orbimed, Google Ventures, Borealis Ventures, Polaris Partners, and SV Health Investors.